Esperion Therapeutics | ESPR

Esperion Therapeutics traded at $5.90 this Friday February 3rd, decreasing $0.02 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Esperion Therapeutics lost 1.99 percent. Over the last 12 months, its price rose by 65.27 percent. Looking ahead, we forecast Esperion Therapeutics to be priced at 5.71 by the end of this quarter and at 5.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
5.90
Daily Change
-0.34%
Yearly
65.27%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Daiichi Sankyo 4,061.00 21.00 0.52% 75.80%
AbbVie 145.20 0.36 0.25% 3.24%
Alnylam Pharmaceuticals 233.37 3.62 1.58% 60.48%
Amgen 245.17 -1.36 -0.55% 10.38%
Amarin 1.89 -0.06 -3.08% -48.36%
Biogen 283.63 -3.89 -1.35% 28.03%
BioMarin Pharmaceutical 112.20 -0.64 -0.57% 26.59%
Cytokinetics 45.01 0.45 1.01% 33.56%
Esperion Therapeutics 5.90 -0.02 -0.34% 65.27%
Geron 3.22 -0.12 -3.59% 218.81%
Halozyme Therapeutics 52.65 -0.22 -0.42% 56.23%
Heron Therapeutics 2.84 -0.06 -2.07% -66.74%
Intercept Pharmaceuticals 19.02 -0.13 -0.68% 24.23%
Ionis Pharmaceuticals 40.92 -0.28 -0.68% 29.90%
Intra Cellular Therapies 48.92 -0.82 -1.65% 0.41%
Eli Lilly 339.08 8.38 2.53% 39.96%
Merck & Co 102.94 -0.52 -0.50% 31.03%
Moderna Inc 173.25 -3.10 -1.76% 6.28%
Minerva Neurosciences 2.87 0.35 13.89% 282.67%
Nektar Therapeutics 3.09 0.09 3.00% -70.46%
Puma Biotechnology 4.46 0.09 2.06% 84.30%
Pfizer 44.06 -0.28 -0.63% -16.87%
PTC Therapeutics 48.04 0.68 1.44% 14.14%
Regeneron Pharmaceuticals 783.13 31.93 4.25% 25.71%
Sanofi 85.02 -1.75 -2.02% -5.84%
Seattle Genetics 138.00 -1.43 -1.03% 0.05%
Sarepta Therapeutics 119.00 -1.25 -1.04% 62.77%
United Therapeutics 252.80 -6.68 -2.57% 25.40%
Vanda Pharmaceuticals 7.65 -0.18 -2.30% -36.41%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
US2000 1986 -15.69 -0.78% -0.84%

Esperion Therapeutics
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.